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Abstract It is well established that only a fraction of Ab
peptides in the brain of Alzheimer’s disease (AD) patients
start with N-terminal aspartate (Ab1D) which is generated
by proteolytic processing of amyloid precursor protein
(APP) by BACE. N-terminally truncated and pyrogluta-
mate modiﬁed Ab starting at position 3 and ending with
amino acid 42 [Ab3(pE)–42] have been previously shown to
represent a major species in the brain of AD patients. When
compared with Ab1–42, this peptide has stronger aggrega-
tion propensity and increased toxicity in vitro. Although it
is unknown which peptidases remove the ﬁrst two N-ter-
minal amino acids, the cyclization of Ab at N-terminal
glutamate can be catalyzed in vitro. Here, we show that
Ab3(pE)–42 induces neurodegeneration and concomitant
neurological deﬁcits in a novel mouse model (TBA2
transgenic mice). Although TBA2 transgenic mice exhibit
a strong neuronal expression of Ab3–42 predominantly in
hippocampus and cerebellum, few plaques were found in
the cortex, cerebellum, brain stem and thalamus. The levels
of converted Ab3(pE)-42 in TBA2 mice were comparable to
the APP/PS1KI mouse model with robust neuron loss and
associated behavioral deﬁcits. Eight weeks after birth
TBA2 mice developed massive neurological impairments
together with abundant loss of Purkinje cells. Although the
TBA2 model lacks important AD-typical neuropathologi-
cal features like tangles and hippocampal degeneration, it
clearly demonstrates that intraneuronal Ab3(pE)–42 is neu-
rotoxic in vivo.
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Introduction
Long-standing evidence shows that progressive cerebral
deposition of Ab plays a seminal role in the pathogenesis
of Alzheimer’s disease (AD). There has been great interest,
therefore, in understanding the proteolytic processing of
APP and the enzymes responsible for cleaving at the
N- and C-termini of the Ab region. Besides Ab peptides
starting with an aspartate at position 1, a variety of dif-
ferent N-truncated Ab peptides has been identiﬁed in AD
brains. Ragged peptides with a major species beginning
with phenylalanine at position 4 of Ab have been reported
as early as 1985 by Masters et al. [36]. This ﬁnding has
been disputed, as no N-terminal sequence could be
obtained from cores puriﬁed in a sodium dodecyl sulfate-
containing buffer, suggesting that the N-terminus is
blocked [16, 59]. In 1992, Mori et al. ﬁrst described
the presence of Ab3(pE) using mass spectrometry of puriﬁed
Ab protein from AD brains, explaining the difﬁculties in
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only 10–15% of the total Ab isolated by this method begins
at position 3 with Ab3(pE). Saido et al. [52] showed for the
ﬁrst time that Ab3(pE) represents an important fraction of
Ab peptides in AD brain, which was later veriﬁed by other
reports using AD and Down’s syndrome post-mortem brain
tissue [18, 19, 23, 25, 28, 29, 38, 45, 46, 49, 53, 63].
N-terminal deletions in general enhance aggregation of
b-amyloid peptides in vitro [47]. Ab3(pE) has a higher
aggregation propensity [20, 55], and stability [30],
and shows an increased toxicity compared with full-length
Ab [51].
Mouse models mimicking AD-typical pathology, such
as deﬁcits in synaptic transmission [24], changes in
behavior, differential glutamate responses, and deﬁcits in
long-term potentiation are typically based on the over-
expression of full-length amyloid precursor protein
(APP) [39]. Learning deﬁcits [2, 21, 43, 48] were evi-
dent in different APP models, however, Ab-amyloid
deposition did not correlate with the behavioral pheno-
type [22]. In the past, Ab has been regarded as acting
extracellularly, whereas recent evidence points to toxic
effects of Ab in intracellular compartments [64, 68]. In
addition, another concept favors that toxic forms of Ab
are soluble oligomers and b-sheet containing amyloid
ﬁbrils [26, 58]. It has been demonstrated that soluble
oligomeric Ab42, but not plaque-associated Ab correlates
best with cognitive dysfunction in AD [37, 42]. Oligo-
meres are formed, preferentially, intracellularly within
neuronal processes and synapses rather than extracellu-
larly [60, 66]. Previously, we have reported that
intraneuronal Ab rather than extracellular plaque
pathology correlates with neuron loss in the hippocampus
[8], the frontal cortex [11], and the cholinergic system
[10] of APP/PS1KI mice expressing transgenic human
mutant APP751 including the Swedish and London
mutations on a murine knock-in (KI) Presenilin 1 (PS1)
background with two FAD-linked mutations (PS1M233T
and PS1L235P). The APP/PS1KI mice exhibit robust
and learning deﬁcits at the age of 6 months [67], age-
dependent axonopathy [71], neuron loss in hippocampus
CA1 together with synaptic deﬁcits, and hippocampus
atrophy coinciding with intraneuronal aggregation of
N-terminal-modiﬁed Ab variants [4].
The APP/PS1KI mouse model exhibits a large hetero-
geneity of N-truncated Abx–42 variants [8]. It is impossible
to decipher the true toxic peptides from those, which might
only co-precipitate. Therefore, we generated a new mouse
model expressing only N-truncated Ab3(pE) in neurons, and
demonstrate for the ﬁrst time that this peptide is neurotoxic
in vivo inducing neuron loss and an associated neurological
phenotype.
Materials and methods
Transgenic mice
The generation of murine thyrotropin-releasing hormone-
Ab fusion protein mTRH-Ab3Q–42 was essentially as
described elsewhere [12]. The respective cDNA was
inserted into the vector pUC18 containing the murine Thy-
1 sequence applying standard molecular biology tech-
niques and veriﬁed by sequencing. The transgenic mice
were generated by male pronuclear injection of fertilized
C57Bl/6J oocytes (PNI, generated by genOway, Lyon,
France). The resulting offspring were further characterized
for transgene integration by PCR analysis and after cross-
ing to C57Bl/6J wildtype mice for transgene expression by
RT-PCR. The line with the highest transgene mRNA
expression was selected for further breeding (named
TBA2).
The generation of APP/PS1KI mice (a generous gift by
Dr. Laurent Pradier, Sanoﬁ-Aventis, Paris) has been
described previously [8]. All mice named as PS1KI were
homozygous for the mutant PS1 knock-in transgene (KI).
The APP/PS1KI mice harbored one hemizygous
APP751SL transgene in addition to homozygous PS1KI.
The mice were backcrossed for more than ten generations
on a C57BL/6J genetic background. APP/PS1KI were
crossed with PS1KI mice generating again APP/PS1KI and
PS1KI mice, therefore, all offspring carried homozygous
PS1KI alleles. All animals were handled according to the
German guidelines for animal care.
Immunohistochemistry and histology
Mice were anaesthetized and transcardially perfused with
ice-cold phosphate-buffered saline (PBS) followed by 4%
paraformaldehyde. Brain samples were carefully dissected
and post-ﬁxed in 4% phosphate-buffered formalin at 4C.
Immunohistochemistry was performed on 4 lm parafﬁn
sections. The following antibodies were used: 4G8
(Ab17-24, Signet), GFAP (Chemicon), Iba1 (Waco),
ubiquitin (DAKO), AT8 (Innogennetics), PS199 (Bio-
source), activated caspase-3 (Chemicon), calbindin
(Swant), and 2 antibodies against Ab with pyroglutamate at
position 3 (a generous gift of Dr. Takaomi Saido [52];
American Research Products). Biotinylated secondary anti-
rabbit and anti-mouse antibodies (1:200) were purchased
from DAKO. Staining was visualized using the ABC
method, with a Vectastain kit (Vector Laboratories) and
diaminobenzidine as chromogen. Counterstaining was
carried out with hematoxylin. For ﬂuorescent staining,
AlexaFluor488- and AlexaFluor594-conjugated antibodies
(Molecular Probes), was used.
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123Quantiﬁcation of Abx–42 and Ab3(pE) by ELISA
Brains were weight in frozen state and directly homoge-
nized in a Dounce-homogenizer in 2.5 ml 2% SDS,
containing complete protease inhibitor (Roche). Homoge-
nates were soniﬁed for 30 s and subsequently centrifuged
at 80,000g for 1 min at 4C. Supernatants were directly
frozen at -80C. The resulting pellets were resuspended in
0.5 ml 70% formic acid (FA) and soniﬁed for 30 s. Formic
acid was neutralized with 9.5 ml 1 M Tris and aliquots
were directly frozen at -80C. SDS lysates were used in a
10-fold dilution for both Abx–42 and AbN3(pE) ELISAs.
Formic acid lysates were used in a 10-fold dilution for the
Abx–42 measurement. For Ab3(pE) measurements undiluted
FA lysates were used. ELISA measurements were per-
formed according to the protocol of the manufacturer (IBL
Co., Ltd. Japan; cat. no. JP27716 and JP27711). For
statistical analyses, Abx–42 and Ab3(pE) concentrations
resulting from SDS and formic acid extractions were
cumulated.
Statistical analysis
Differences between the groups were tested with one-way
analysis of variance (ANOVA) followed by unpaired t
tests. All data are given as mean ± SEM. Signiﬁcance
levels of unpaired t tests are given as follows:
***P\0.001; **P\0.01; *P\0.05. Survival rate was
calculated by the Log-rank test. All calculations were
performed using GraphPad Prism version 4.03 for Win-
dows (GraphPad Software, San Diego, CA, USA).
Results
Generation of transgenic TBA2 mouse line
In addition to Ab starting with aspartate at position 1
(Ab1D), one major Ab species in AD brain starts at position
3 with pyroglutamate (Ab3(pE)) that can be converted from
N-terminal glutamate (Ab3E) or glutamine (Ab3Q) (Fig. 1a).
We generated a novel mouse model that expresses Ab3–42
peptides under the control of the Thy-1 promoter. The
TBA2 line expresses Ab with N-terminal glutamine
(Ab3Q–42) as a fusion protein with the pre-pro-sequence of
murine thyrotropin-releasing hormone (mTRH) (Fig. 1b),
for transport via the secretory pathway [12].
Phenotypic characterization of TBA2 mice
The TBA2 transgenic mice revealed obvious macroscopic
abnormalities, including growth retardation, cerebellar atro-
phy, premature death (Fig. 2), and a striking neurological
phenotype characterized by loss of motor coordination and
ataxia (Supplementary videos 1–3). The body weight at
2 months of age was signiﬁcantly reduced in TBA2 mice
(females 12.20 ± 0.95 g, males 17.60 ± 0.51 g), compared
with wildtype (WT) control littermates (females 19.90 ±
0.40 g, males 24.43 ± 1.23 g, both P\0.001). Only one of
threeTBA2foundermicewasfertile,andwasstudiedinmore
detailed manner (named TBA2 line).
Quantiﬁcation of Abx–42 and Ab3(pE) levels
Protein quantiﬁcation of Abx–42 and Ab3(pE) levels in brain
lysates WT, APP/PS1KI, and TBA2 mice revealed signif-
icant differences (Fig. 3). Although WT mice generated
very low amounts of murine Abx–42 (WT, 1.29 ± 0.9
pg/mg w.w.), 2-month-old APP/PS1KI mice showed high
Abx–42 levels (35,191 ± 773.1 pg/mg w.w.), which were
increased in 6-month-old APP/PS1KI mice 58.063 ±
14.027 pg/mg w.w.). The Abx–42 levels in 2-month-old
TBA2 mice (410.2 ± 43.04 pg/mg w.w.) were *85-fold
lower than in age-matched APP/PS1KI mice, which
reﬂects the considerable plaque load already present in
APP/PS1KI mice at that time point. (Fig. 3a). In WT mice
Fig. 1 Sequence of Ab1–42 and N-terminal truncated Ab starting at
position 3. a Ab1–42 starts at position 1 with aspartate (D), Ab3E–42 at
position 3 with glutamate (E), and Ab3Q–42 with glutamine (Q). Both
N-truncated Ab3E–42 and Ab3Q–42 peptides can be converted into
pyroglutamate-Ab3(pE)–42. b Schematic drawing of the transgenic
vector. TBA2 transgenic mice express Ab3(Q)–42 under the control of
the Thy1 promoter fused to the signal peptide of the pre-pro-
thyrotropin-releasing hormone. c N-terminal Ab starting with gluta-
mate (Ab3E) or glutamine (Ab3Q) at position 3 serves as substrates for
generation of Ab3(pE). The conversion of pyroglutamate from N-
terminal glutamate (E) is slow, in contrast to fast pyroglutamate (pE)
formation from glutamine (Q)[ 12]
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123Ab3(pE) was undetectable by ELISA (Fig. 3b). APP/PS1KI
mice at 2 months of age showed detectable Ab3(pE) levels
(2.120 ± 0.017 pg/mg w.w.), which increased *43-fold
in 6-month-old APP/PS1KI mice (91.32 ± 26.16 pg/mg
w.w.). Analysis of TBA2 mice (53.23 ± 9.18 pg/mg w.w.)
also revealed considerable high Ab3(pE) levels, which were,
however, signiﬁcantly lower than in the 6-month-old APP/
PS1KI mice (P\0.05) (Fig. 3b). Interestingly, TBA2 mice
revealed a more than 50-fold Ab3(pE)/Abx–42 increased ratio
than 6-month-old APP/PS1KI mice (0.1313 ± 0.03 vs.
0.0023 ± 0.0007; P\0.001), conﬁrming the assumption
that TBA2 mice produce high amounts of modiﬁed
Fig. 2 Characterization of
TBA2 transgenic mice. Picture
of a wildtype (WT) and a TBA2
mouse showing that TBA2 mice
are generally smaller (a) and
that they display a crooked
posture (b). c Both female and
male TBA2 mice showed a
reduced body weight compared
with their age-matched WT
littermates. d Macroscopic
analysis of TBA2 brains
revealed an atrophic cerebellum
when compared with age-
matched WT littermates.
e TBA2 mice displayed a
signiﬁcantly reduced survival
rate compared with WT
littermates (P = 0.0002;
Logrank test)
Fig. 3 ELISA measurements of Abx–42 and Ab3(pE) in brain hemi-
sphere lysates of WT, APP/PS1KI and TBA2 mice. The Abx–42 levels
in 2-month-old TBA2 mice were *85-fold lower than in age-
matched APP/PS1KI mice (a). APP/PS1KI mice at 2 months of age
showed detectable Ab3(pE) levels increasing *43-fold in 6-month-old
mice. TBA2 mice also revealed considerable high Ab3(pE) levels,
which were, however, signiﬁcantly lower than in the 6-month-old
APP/PS1KI mice (P\0.05) (b). TBA2 mice revealed a more than
50-fold higher Ab3(pE)/Abx–42 ratio compared with 6-month-old APP/
PS1KI mice (P\0.001) (c)
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123Ab3(pE–42) (Fig. 3c). The same proﬁle was obtained by
Western blot analysis (Supplementary Fig. 1).
Neuropathological assessment of TBA2 mice
Consistently, TBA2 brain sections showed strong immu-
noreactivity using antibody 4G8 against Ab (epitope 17–
24) predominantly in CA1 pyramidal neurons and in Pur-
kinje cells (Fig. 4a, c, d). Neurons in other brain areas were
also positive, but the immunoreactivity was less abundant.
Diffuse plaques were observed in many brain areas
including cortex, cerebellum, thalamus (Fig. 4b), and other
areas, but were less prominent as compared to intraneu-
ronal staining (Table 1). Interestingly, low number of
plaques were detected in the cerebellar white matter (not
shown), whereas most Ab immunoreactivity was found
associated with Purkinje cells (Fig. 4c–e). The observation
of extracellular plaques in many brain ares demonstrates
that Ab is also secreted. The neurological phenotype of the
TBA2 line resembles that of mouse models with Purkinje
cell degeneration (for example [5]). Many, but not all,
Purkinje cells were positive for Ab3(pE) (Fig. 4e, f).
Neuropathological analysis of TBA2 mice demonstrated
neurodegeneration of Purkinje cells by several observa-
tions: abundant micro- and astrogliosis was observed in the
cerebellar molecular layer (Fig. 4g–j). Double stainings
using 4G8 (red) and ubiquitin (green) showed a colocal-
ization of Ab peptides and ubiquitin, a marker for protein
degradation in the cerebellar Purkinje cell layer (Fig. 4k).
In addition, double stainings revealed Ab peptides within
calbindin-positive Purkinje cells (arrows and inset in
Fig. 4i) and indicated a loss of calbindin-positive Purkinje
cells Fig. 4l, m). Interestingly, we observed extracellular
Ab deposition, which was associated with the site of Pur-
kinje cell loss (asterisk in Fig. 4m). The neuropathological
observations correlate well with the age-dependent neuro-
logical deﬁcits (Supplementary videos 1–3) and cerebellar
atrophy in the TBA2 model (Fig. 2d). We did not observe
any staining using antibodies against hyperphosphorylated
Tau (AT8 and PS199) or activated caspase-3 (a marker for
apoptosis). Double staining of Ab and cathepsin D revealed
a partial overlap demonstrating intracellular distribution in
the late endosomal/lysosomal compartment (Supplemen-
tary Fig. 2).
Discussion
Mice transgenic for the human APP gene have been
proven valuable model systems for AD research. Early
pathological changes, including deﬁcits in synaptic trans-
mission [24], changes in behavior, differential glutamate
responses, and deﬁcits in long-term potentiation [39] have
been reported in several studies. In addition, learning
deﬁcits [2, 15, 21, 43, 48] and reduced brain volume [4]
were evident in transgenic APP models. Interestingly,
extracellular amyloid deposition did not correlate with the
behavioral phenotype [22, 67]. These deﬁcits occurred
well before plaque deposition became prominent and may,
therefore, reﬂect early pathological changes, likely
induced by intraneuronal APP/Ab mistrafﬁcking or in-
traneuronal Ab accumulation (reviewed in [1]). The
coincidence of intracellular Ab with behavioral deﬁcits
supporting an early role of intracellular Ab has been
recently demonstrated in a mouse model containing the
Swedish and Arctic mutations [27, 34]. In accordance with
these ﬁndings, we have previously shown that intraneu-
ronal Ab accumulation precedes plaque formation in
transgenic mice expressing mutant APP695 with the
Swedish, Dutch, and London mutations in combination
with mutant PS-1 M146L. These mice displayed abundant
intraneuronal Ab immunoreactivity in hippocampal and
cortical pyramidal neurons [69]. An even more pro-
nounced phenotype was observed in another transgenic
mouse model, expressing Swedish and London mutant
APP751 together with mutant PS-1 M146L [3]. In young
mice, a strong intraneuronal Ab staining was detected in
vesicular structures in somatodendritic and axonal com-
partments of pyramidal neurons and an attenuated
neuronal immunoreactivity with increasing age. The in-
traneuronal immunoreactivity declined with increased
plaque accumulation [70], a ﬁnding which was also
reported in Down’s syndrome patients, where the youngest
patients displayed the strongest immunoreactivity [40].
The neuronal loss in CA1 of the hippocampus did not
correlate with the amount of extracellular Ab [4, 8]. The
same observation has been reported in the APP/
PS1M146L model [57]. Hippocampal neuron loss has also
been reported in the APP23 mouse model [7], however
whether intraneuronal Ab contributes to the neuron loss in
this model is not clear. The triple-transgenic mouse model
expresses mutant APP in combination with mutant PS-1
and mutant Tau protein. These mice displayed early
synaptic dysfunction before plaque or tangle deposition
was evident, together with early intraneuronal Ab immu-
noreactivity preceding plaque deposition. Tau and Ab
immunoreactivity colocalized in hippocampal neurons,
which might imply that early intraneuronal Ab accumu-
lation could affect Tau pathology [44]. All these AD
mouse models express full-length APP, and also C-ter-
minal fragments and Ab peptides after cleavage. It is,
therefore, difﬁcult to decipher the pathological function of
speciﬁc Ab peptides.
In order to speciﬁcally investigate the neurotoxicity of
Ab3pE–42 generation in vivo, we have generated transgenic
mice expressing Ab3Q–42 starting at position 3 with
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Owing to the replacement of N-terminal glutamate by
glutamine, the Ab peptides are more prone to conversion
into pyroglutamate [54]. The severity of the neurological
phenotype observed in TBA2 mice, accompanied with the
Purkinje cell loss and premature mortality reﬂects the in
vivo toxicity of Ab3(pE)–42. However, we cannot rule out
that unprocessed Ab3Q–42 has been stabilized by Ab3(pE)–42
accumulation, and might also contribute to the observed
neurological phenotype. In addition, the level of Ab3(pE)–42
Fig. 4 Immunohistochemical staining of TBA2 mouse brain (2-
month-old). a Immunostaining with 4G8 revealed strong Ab accu-
mulation in the CA1 pyramidal layer of the hippocampus (inset shows
a hippocampus overview at low magniﬁcation). b Intra- (arrowhead)
and extracellular Ab (asterisk) in the thalamus shown by 4G8
staining. c, d Ab staining (4G8) in the cerebellum is almost
completely restricted to the Purkinje cell layer. e, f Most Purkinje
cells accumulated pyroglutamate-Ab as shown by an antibody against
Ab3(pE). g GFAP staining of a TBA2 mouse revealed prominent
Bergmann glia immunoreactivity, whereas wildtype animals (h) were
consistently negative. The microglia marker Iba1 revealed microglia
clusters surrounding Purkinje cells and in white matter tracts in TBA2
mice (i), but not in wildtype littermates (j). k Immunostaining of
Purkinje cells with 4G8 (red) and anti-ubiquitin (green) antibodies
showing abundant ubiquitin immunoreactivity in 4G8-positive Pur-
kinje cells. l, m Staining of Purkinje cells using antibodies against
calbindin (green) and 4G8 (inset shows high magniﬁcation of a 4G8-
and calbindin-positive Purkinje cell). Note absent calbindin (asterisk)
and extracellular Ab staining indicating Purkinje cell loss. Only 4G8-
positive remnants can be seen. Scale bars a, d, e, g–j 100 lm; b, k–m
50 lm; c 500 lm; f inset k, l 20 lm
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123in 6-month-old APP/PS1KI mice was comparable to that of
2-month-old TBA2 mice. However, 85% of Ab peptides in
the APP/PS1KI mice terminated at position 42, the N-ter-
minus shows a large heterogeneity including Ab3(pE). The
time point of high levels of Ab3(pE)–42 coincided with the
onset of behavioral deﬁcits in both mouse models. In
addition, only a fraction of Purkinje cells showed abundant
levels of intracellular Ab3(pE) accumulation leading to the
assumption that only those are prone for degeneration
(Fig. 4). We have previously shown that at 6 months, the
APP/PS1KI mice exhibit a neuron loss in CA1 of the
hippocampus [4, 8], the frontal cortex [11], and in distinct
cholinergic nuclei [10]. Recently, a transgenic mouse
model expressing human APP with the 714 austrian
mutation has been reported showing intraneuronal Ab
accumulation correlating with brain atrophy [65]. Overall,
the pathological events seen in the APP/PS1KI mouse
model might be at least partly triggered by Ab3(pE)–42
accumulation however the TBA2 mouse model is the only
one expressing Ab3(pE)–42 without any of the other Ab
peptides.
Amyloid precursor protein transgenic mouse models
have been reported to show no [29] or low Ab3(pE) levels
[18]. Maeda et al. have demonstrated that the localization
and abundance of [11C]PIB autoradiographic signals were
closely associated with those of amino-terminally truncated
and modiﬁed Ab3pE deposition in AD and different APP
transgenic mouse brains, implying that the detectability of
amyloid by [11C]PIB-PET is dependent on the accumula-
tion of speciﬁc Ab subtypes [35]. There is an interesting
coincidence of considerable amounts of Ab3(pE) and mas-
sive neuron loss in the APP/PS1KI mouse model [1, 8]. An
emerging role of intracellular Ab accumulation has been
previously shown in human AD [13, 17]. It has been
observed that Ab localizes predominantly to abnormal
endosomes [9], multivesicular bodies, and within pre- and
postsynaptic compartments [31, 61]. Takahashi et al.
demonstrated that Ab42 aggregates into oligomers within
endosomal vesicles and along microtubules of neuronal
processes, both in Tg2576 neurons with time in culture, as
well as in Tg2576 and human AD brain [60]. In good
agreement with these reports, we observed that Ab is also
localized in the late endosomal/lysosomal compartment in
the TBA2 model. Owing to the large heterogeneity of
N-truncated Abx–42 peptides in the APP/PS1KI model, it is
impossible to study the role of a single Ab variant. In the
TBA2 model, however, we were able to demonstrate the
intraneuronal Ab3(pE)–42 aggregation induced neuron loss
without contribution of extracellular Ab aggregation.
N-truncated Ab3(pE) peptides have been identiﬁed by
several groups from AD brains [18, 19, 23, 25, 28, 29, 38,
41, 45, 46, 49, 52, 53, 63]. In addition, other N-terminal
truncated peptides have been identiﬁed such as Ab5–40/42
[62], Ab11–40/42 [32, 33], and Flemish and Dutch N-ter-
minally truncated amyloid beta peptides [14]. Cai et al.
have demonstrated that secretion of Ab1–40/42 and Ab11–40/
42 is abolished in BACE1-/- neurons establishing that
BACE1 is the principal b-secretase for endogenous APP in
neurons. Although Ab11–40/42 peptides have been observed
in neuronal cultures and in the brains of patients with AD,
the involvement of these peptides in its pathogenesis
remains to be elusive [6]. In general, N-terminal deletions
enhance aggregation of b-amyloid peptides in vitro [47].
Ab3(pE) has a higher aggregation propensity [20, 55] and
stability [30], and shows an increased toxicity compared
with full-length Ab [51]. It has been suggested that
N-truncated Ab peptides are formed directly by BACE
and not through a progressive proteolysis of full-length
Ab1–40/42 [50].
In in vitro experiments Schilling et al. have shown that
the cyclization of glutamate at position 3 of Ab is driven
enzymatically by glutaminyl cyclase (QC) [54]. In addi-
tion, it has been shown that QC inhibition signiﬁcantly
reduced Ab3(pE) formation, emphasizing the importance of
QC activity during the cellular maturation of pyrogluta-
mate-containing peptides. The pharmacological inhibition
of QC activity by the QC inhibitor P150, which signiﬁ-
cantly reduced the level of Ab3(pE) in vitro [12] and in vivo
[56] suggests that QC inhibition might serve as a new
therapeutic approach to rescue Ab3(pE) triggered neurode-
generation in human disorders.
Ab accumulation has an important function in the eti-
ology of AD with its typical clinical symptoms, such as
memory impairment and changes in personality. However,
the mode of this toxic activity is still a matter of scientiﬁc
debate. Previously, we have shown that the APP/PS1KI
Table 1 Distribution and semi-quantitative description of intraneu-
ronal and plaque-associated Ab pathology based on 4G8 immuno-
staining
Brain region Intraneuronal Ab Plaques
Olfactory bulb ??
Cortex ?/?? ?
Hippocampus ??? -
Thalamus (?) ??
Superior colliculus ?? ??
Midbrain ??
Pons ?? ?
Medulla ?? ?/??
Cerebellum
Purkinje cell layer ??? -
White matter -? ?
Granule cell layer --
Molecular layer --
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123mouse model develops severe learning deﬁcits at 6 months
of age correlating with a CA1 neuron loss and an atrophy
of the hippocampus [4, 8], together with a drastic reduction
of long-term potentiation and disrupted paired pulse facil-
itation. This was accompanied by reduced levels of pre-
and post-synaptic markers. We also observed that intran-
euronal and not plaque-associated Ab including N-
modiﬁed Ab3(pE)–42 species increased and coincided well
with CA1 neuron loss, however the dominant species was
Ab1–42 in the APP/PS1KI model. In good agreement with
this study, we could show for the ﬁrst time that intraneu-
ronal Ab3(pE)–42 accumulation is sufﬁcient for triggering
neuron death and inducing an associated neurological
phenotype in a novel transgenic mouse model (TBA2
mice). The Ab staining in the cerebellum was completely
restricted to the intraneuronal compartment further sup-
porting the notion that intraneuronal pathology is
instrumental in neuron loss and that extracellular plaque
deposition has no drastic effect on cell survival.
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